MicrobioticaCambridge-based Microbiotica’s ulcerative colitis (UC) candidate met its primary and secondary phase 1b study objectives on safety, efficacy signals and bacterial engraftment. The company has reported positive results from a small, placebo-controlled study of its oral precision microbiome therapy MB310 in patients with mild-to-moderate ulcerative colitis, adding a rare positive clinical signal in a disease area where microbiome approaches have so far struggled to gain traction.
Tag Archive for: inflammatory
Munich-based microbiome therapeutics specialist mbiomics GmbH has raised €13m in the first closing of Series A round led by MIG Capital.